Spalt-like transcription factor 4 (SALL4), a cancer stem cell (CSC) marker (Islam et al. 2015), has been identified as a promising biomarker and diagnostic/therapeutic target owing to its overexpression in various cancers, including GIT cancers, with adverse progression and poor outcomes (Zhang et al. 2015; Sun et al. 2022; Dirican and Akkiprik 2016; Yong et al. 2013). Here, SALL4 is linked to cancer.